James Christensen
Harvard University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by James Christensen.
Journal of Clinical Oncology | 2016
Mark M. Awad; Geoffrey R. Oxnard; David M. Jackman; Daniel O. Savukoski; Dimity Hall; Priyanka Shivdasani; Jennifer C. Heng; Suzanne E. Dahlberg; Pasi A. Jänne; Suman Verma; James Christensen; Peter S. Hammerman; Lynette M. Sholl
PURPOSE Non-small-cell lung cancers (NSCLCs) harboring mutations in MET exon 14 and its flanking introns may respond to c-Met inhibitors. We sought to describe the clinical, pathologic, and genomic characteristics of patients with cancer with MET exon 14 mutations. PATIENTS AND METHODS We interrogated next-generation sequencing results from 6,376 cancers to identify those harboring MET exon 14 mutations. Clinical characteristics of MET exon 14 mutated NSCLCs were compared with those of NSCLCs with activating mutations in KRAS and EGFR. Co-occurring genomic mutations and copy number alterations were identified. c-Met immunohistochemistry and real-time polymerase chain reaction to detect exon 14 skipping were performed where sufficient tissue was available. RESULTS MET exon 14 mutations were identified in 28 of 933 nonsquamous NSCLCs (3.0%) and were not seen in other cancer types in this study. Patients with MET exon 14-mutated NSCLC were significantly older (median age, 72.5 years) than patients with EGFR-mutant (median age, 61 years; P < .001) or KRAS-mutant NSCLC (median age, 65 years; P < .001). Among patients with MET exon 14 mutations, 68% were women, and 36% were never-smokers. Stage IV MET exon 14-mutated NSCLCs were significantly more likely to have concurrent MET genomic amplification (mean ratio of MET to chromosome 7, 4.3) and strong c-Met immunohistochemical expression (mean H score, 253) than stage IA to IIIB MET exon 14-mutated NSCLCs (mean ratio of MET to chromosome 7, 1.4; P = .007; mean H score, 155; P = .002) and stage IV MET exon 14-wild-type NSCLCs (mean ratio of MET to chromosome 7, 1.2; P < .001; mean H score, 142; P < .001). A patient whose lung cancer harbored a MET exon 14 mutation with concurrent genomic amplification of the mutated MET allele experienced a major partial response to the c-Met inhibitor crizotinib. CONCLUSION MET exon 14 mutations represent a clinically unique molecular subtype of NSCLC. Prospective clinical trials with c-Met inhibitors will be necessary to validate MET exon 14 mutations as an important therapeutic target in NSCLC.
Biological Psychiatry | 1997
Perry F. Renshaw; Beny Lafer; Suzann M. Babb; Maurizio Fava; Andrew L. Stoll; James Christensen; Constance M. Moore; Deborah A. Yurgelun-Todd; Christina M. Bonello; Srinivasan S. Pillay; Anthony J. Rothschild; Andrew A. Nierenberg; Jerrold F. Rosenbaum; Bruce M. Cohen
We have investigated proton magnetic resonance spectra of the basal ganglia in 41 medication-free outpatients with major depression, prior to starting an 8-week standardized trial of open-label fluoxetine, and 22 matched comparison subjects. Upon completing the trial, depressed subjects were classified as treatment responders (n = 18) or nonresponders (n = 23), based on changes in the Hamilton Depression Rating Scale. Depressed subjects had a lower area ratio of the choline resonance to the creatine resonance (Cho/Cr) than comparison subjects. This statistically significant difference between the depressed subjects and comparison subjects was more pronounced in the treatment responders than in the nonresponders. There were no differences in the relative volumes of gray matter or white matter in the voxel used for proton spectroscopy in depressed subjects relative to comparison subjects. These results are consistent with an alteration in the metabolism of cytosolic choline compounds in the basal ganglia of depressed subjects and, in particular, those who are responsive to fluoxetine.
Biological Psychiatry | 1996
Andrew L. Stoll; Gary S. Sachs; Bruce M. Cohen; Beny Lafer; James Christensen; Perry F. Renshaw
This study examined choline augmentation of lithium for rapid-cycling bipolar disorder. Choline bitartrate was given openly to 6 consecutive lithium-treated outpatients with rapid-cycling bipolar disorder. Five patients also underwent brain proton magnetic resonance spectroscopy. Five of 6 rapid-cycling patients had a substantial reduction in manic symptoms, and 4 patients had a marked reduction in all mood symptoms during choline therapy. The patients who responded to choline all exhibited a substantial rise in the basal ganglia concentration of choline-containing compounds. Choline was well tolerated in all cases. Choline, in the presence of lithium, was a safe and effective treatment for 4 of 6 rapid-cycling patients in our series. A hypothesis is suggested to explain both lithium refractoriness in patients with bipolar disorder and the action of choline in mania, which involves the interaction between phosphatidylinositol and phosphatidylcholine second-messenger systems.
Brain Research | 1999
James Christensen; Deborah A. Yurgelun-Todd; Suzann M. Babb; Staci A. Gruber; Bruce M. Cohen; Perry F. Renshaw
OBJECTIVE The goals of this study were to quantitate the brain concentration of the anorectic drug dexfenfluramine (DF) in human subjects receiving clinical doses of DF and to determine whether human brain DF concentrations approach those reported to cause irreversible neurochemical changes in animals. Each subjects brain DF concentration was measured several times over an extended period of DF treatment to determine whether drug accumulation in the brain would plateau or continue to increase throughout the treatment period. DESIGN Fluorine magnetic resonance spectroscopy (19F-MRS) was used to directly detect and quantitate brain levels of the fluorinated drug dexfenfluramine and its active metabolite dex-norfenfluramine (dNF). Patients received 15 mg dexfenfluramine BID for 90 days. 19F-MRS measurements were performed at baseline and at three times during the treatment period. PARTICIPANTS Twelve women (age 38-54 years) who were obese, with body mass indices of 28. 4-37.4, but otherwise healthy. RESULTS The combined concentration of DF and nDF reached steady-state in the human brain after approximately 10 days of treatment. The steady-state brain concentration averaged approximately 4 microM and did not tend to increase significantly during the 90 day treatment period. CONCLUSIONS These results demonstrate that fluorinated drugs can be quantified using 19F MRS at concentrations below 10 microM in the human brain. The time-course data suggest that brain DF concentrations parallel DF plasma pharmacokinetics in humans. Measured brain dexfenfluramine/nor-dexfenfluramine concentrations were well below levels previously found to cause irreversible brain alterations in animals.
Biological Psychiatry | 2000
James Christensen; Marc J. Kaufman; Blaise deB. Frederick; Stephanie L. Rose; Constance M. Moore; Scott E. Lukas; Jack H. Mendelson; Bruce M. Cohen; Perrv F. Renshaw
BACKGROUND Proton magnetic resonance spectroscopy was used to determine the effects of intravenous cocaine or placebo administration on human basal ganglia water and metabolite resonances. METHODS Long echo time, proton magnetic resonance spectra of water and intracellular metabolites were continuously acquired from an 8-cm(3) voxel centered on the left caudate and putamen nuclei before, during, and after the intravenous administration of cocaine or a placebo in a double-blind manner. RESULTS Cocaine, at both 0.2 and 0.4 mg/kg, did not alter the peak area for water. Cocaine at 0.2 mg/kg induced small and reversible increases in choline-containing compounds and N-acetylaspartate peak areas. Cocaine at 0.4 mg/kg induced larger and more sustained increases in choline-containing compounds and N-acetylaspartate peak areas. No changes in either water or metabolite resonances were noted following placebo administration. CONCLUSIONS These increases in choline-containing compounds and N-acetylaspartate peak areas may reflect increases in metabolite T2 relaxation times secondary to osmotic stress and/or increased phospholipid signaling within the basal ganglia following cocaine administration. This is the first report of acute, drug-induced changes in the intensity of human brain proton magnetic resonance spectroscopy resonance areas.
Seminars in Clinical Neuropsychiatry | 1996
Marc J. Kaufman; Jonathan M. Levin; James Christensen; Perry F. Renshaw
Magnetic resonance imaging and spectroscopy provide numerous ways to examine the effects of substance abuse on living tissues, ranging from high resolution anatomic imaging to dynamic imaging of tissue biochemical and functional changes. This review focuses on the role magnetic resonance studies have had in detecting brain anatomic changes associated with alcohol, stimulant, and narcotic abuse. Additionally, we focus on the increasing use of spectroscopy and functional magnetic resonance imaging, which can reveal subtle brain changes associated with substance abuse and which offer great promise to help elucidate drug reinforcement mechanisms.
JCO Precision Oncology | 2018
Miriam T. Jacobs; Nisha Mohindra; Lindsey Shantzer; Ingrid L. Chen; Hardeep Phull; William Mitchell; Victoria M. Raymond; Kimberly C. Banks; Rebecca J. Nagy; Richard B. Lanman; James Christensen; Jyoti D. Patel; Jeffrey Melson Clarke; Sandip Pravin Patel
PurposeTo evaluate the clinical outcome of patients with non–small-cell lung cancer treated by targeting low variant allelic frequency (VAF) driver mutations identified through cell-free DNA (cfDNA) next-generation sequencing (NGS). Detection of driver mutations in cancer is critically important in the age of targeted therapy, where both tumor-based as well as cfDNA sequencing methods have been used for therapeutic decision making. We hypothesized that VAF should not be predictive of response and that low VAF alterations detected by cfDNA NGS can respond to targeted therapy.Patients and MethodsA multicenter retrospective case review was performed to identify patients with non–small-cell lung cancer who received targeted molecular therapy on the basis of findings of low VAF alterations in cfDNA NGS. Mutations at low VAF were defined as < 0.2% mutated cfDNA molecules in a background of wild-type cfDNA.ResultsOne hundred seventy-two patients underwent cfDNA NGS testing. Of the 172 patients, 12 were identifie...
American Journal of Psychiatry | 1997
Constance M. Moore; James Christensen; Beny Lafer; Maurizio Fava; Perry F. Renshaw
Magnetic Resonance in Medicine | 1996
James Christensen; Bertrand J. Barrère; Fernando E. Boada; J. Michael Vevea; Keith R. Thulborn
Magnetic Resonance in Medicine | 1996
James Christensen; Marc J. Kaufman; Jonathan M. Levin; Jack H. Mendelson; B. Leonard Holman; Bruce M. Cohen; Perry F. Renshaw